UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Wettability of bare and fluorinated silanes: A combined approach based on surface free energy evaluations and dipole moment calculations

Journal of colloid and interface science, 2013-01, Vol.389 (1), p.284-291

2013

Volltextzugriff (PDF)

Revisión crítica de la evolución tecnológica de la cosecha de la caña de azúcar en la Argentina

RIA. Revista de investigaciones agropecuarias, 2019-01, Vol.45 (1), p.31-43

2019

Volltextzugriff (PDF)

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Annals of oncology, 2020-04, Vol.31 (4), p.495-500

2020

Volltextzugriff (PDF)

SAKK 17/16 - Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, single-arm phase II trial

Annals of oncology, 2018-10, Vol.29, p.viii644-viii644

2018

Volltextzugriff (PDF)

Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small cell lung cancer: A multicenter phase II trial (SAKK 15/12)

Annals of oncology, 2018-10, Vol.29, p.viii597-viii597

2018

Volltextzugriff (PDF)

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

Haematologica (Roma), 2012-07, Vol.97 (7), p.1085-1091

2012

Volltextzugriff (PDF)

LBA30 Single-dose carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B: Efficacy results from the international multicenter phase II trial SAKK 01/10

Annals of oncology, 2021-09, Vol.32, p.S1305-S1305

2021

Volltextzugriff (PDF)

P30.01 Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01)

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S1051-S1051

2021

Volltextzugriff (PDF)

MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09)

Journal of thoracic oncology, 2017-11, Vol.12 (11), p.S1864-S1865

2017

Volltextzugriff (PDF)

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

PloS one, 2015-06, Vol.10 (6), p.e0129648-e0129648

2015

Volltextzugriff (PDF)

A phase 2 trial of ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a AR targeting agent and non-progressive on a second line taxane (SAKK 08/16)

Annals of oncology, 2017-09, Vol.28, p.v290-v291

2017

Volltextzugriff (PDF)

OC-0318: Neurotoxicity of early prophylactic cranial radiation and hippocampal avoidance in SCLC (SAKK 15/12)

Radiotherapy and oncology, 2020-11, Vol.152, p.S167-S167

2020

Volltextzugriff (PDF)

SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial

Annals of oncology, 2019-10, Vol.30, p.v748

2019

Volltextzugriff (PDF)

1843O - SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial

Annals of oncology, 2019-10, Vol.30, p.v748-v748

2019

Volltextzugriff (PDF)

1817TiPSAKK 17/16 - Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, single-arm phase II trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1418PDLONG-TERM OUTCOME OF DASATINIB FIRST-LINE TREATMENT IN GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER TWO STAGE PHASE II TRIAL SAKK 56/07

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv496-iv497

2014

Volltextzugriff (PDF)

Long-Term Outcome of Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors: a Multicenter Two Stage Phase Ii Trial Sakk 56/07

Annals of oncology, 2014-09, Vol.25, p.iv496

2014

Volltextzugriff (PDF)

Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors. a Multicenter Phase II Trial of the SAKK (SAKK 56/07)

Annals of oncology, 2012-09, Vol.23, p.ix480

2012

Volltextzugriff (PDF)

1482PD - Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors. a Multicenter Phase II Trial of the SAKK (SAKK 56/07)

Annals of oncology, 2012-09, Vol.23, p.ix480-ix480

2012

Volltextzugriff (PDF)

1667PDImpact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small cell lung cancer: A multicenter phase II trial (SAKK 15/12)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Bevacizumab plus pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: update from the SAKK19/09 trial

Clinical lung cancer, 2016

2016

Volltextzugriff (PDF)

1843OSAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

OC-0125: Relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 trial

Radiotherapy and oncology, 2017-05, Vol.123, p.S58-S59

2017

Volltextzugriff (PDF)

Abstract P2-16-19: Fulvestrant with or without selumetinib (Sel, AZD6244), a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor (AI): A multicenter randomized placebo-controlled double-blind phase II trial, SAKK21/08

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-16-19

2013

Volltextzugriff (PDF)

Human anti‐IgE antibodies by repertoire cloning

European journal of immunology, 1994-05, Vol.24 (5), p.1200-1207

1994

Volltextzugriff (PDF)

1 – 25 von 174

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(125)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Wettability of bare and fluorinated silanes: A combined approach based on surface free energy evaluations and dipole moment calculations

Revisión crítica de la evolución tecnológica de la cosecha de la caña de azúcar en la Argentina

Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

SAKK 17/16 - Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, single-arm phase II trial

Impact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small cell lung cancer: A multicenter phase II trial (SAKK 15/12)

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

LBA30 Single-dose carboplatin followed by involved-node radiotherapy as curative treatment for seminoma stage IIA/B: Efficacy results from the international multicenter phase II trial SAKK 01/10

P30.01 Extended Resections for Advanced Stages T3/T4 NSCLC After Neoadjuvant Treatment: Conclusions of SAKK Pooled Analysis (16/96, 16/00, 16/01)

MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09)

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

A phase 2 trial of ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a AR targeting agent and non-progressive on a second line taxane (SAKK 08/16)

OC-0318: Neurotoxicity of early prophylactic cranial radiation and hippocampal avoidance in SCLC (SAKK 15/12)

SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial

1843O - SAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial

1817TiPSAKK 17/16 - Lurbinectedin monotherapy in patients with progressive malignant pleural mesothelioma: A multicenter, single-arm phase II trial

1418PDLONG-TERM OUTCOME OF DASATINIB FIRST-LINE TREATMENT IN GASTROINTESTINAL STROMAL TUMORS: A MULTICENTER TWO STAGE PHASE II TRIAL SAKK 56/07

Long-Term Outcome of Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors: a Multicenter Two Stage Phase Ii Trial Sakk 56/07

Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors. a Multicenter Phase II Trial of the SAKK (SAKK 56/07)

1482PD - Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors. a Multicenter Phase II Trial of the SAKK (SAKK 56/07)

1667PDImpact of early prophylactic cranial irradiation with hippocampal avoidance on neurocognitive function in patients with limited disease small cell lung cancer: A multicenter phase II trial (SAKK 15/12)

Bevacizumab plus pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: update from the SAKK19/09 trial

1843OSAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial

OC-0125: Relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 trial

Abstract P2-16-19: Fulvestrant with or without selumetinib (Sel, AZD6244), a mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor (AI): A multicenter randomized placebo-controlled double-blind phase II trial, SAKK21/08

Human anti‐IgE antibodies by repertoire cloning

Suchergebnisse filtern